Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06654414 · ClinicalTrials.gov registry record · NA
Project QUIT+: Adapting and Testing a Smoking Cessation Intervention for Transgender and Gender Expansive Individuals
A NA study, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- NA
- Development phase
- 3
- Enrollment target
NCT06654414: Clinical Trial NA study, sponsored by Massachusetts General Hospital.
NCT06654414 is a NA study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06654414, a NA study, was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- NA
- Development phase
- 3 participants
- Enrollment target
Study Summary
Smoking remains the leading preventable cause of death in the United States, and there are persistent and significant disparities in tobacco use among transgender and gender diverse (TGD) individuals. Stigma, discrimination, gender dysphoria, and other gender minority stressors likely contribute to these disparities, and the increased burden of gender minority stress may also be driving higher prevalence rates of anxiety and depression, both of which are more common among TGD individuals and among those who smoke relative to comparison samples. This study will (1) explore the ways in which gender minority stressors and associated anxiety and depression compromise smoking cessation among TGD individuals, identifying elements in an existing smoking cessation intervention that need to be adjusted to meet their unique needs; (2) adapt an existing smoking cessation intervention for TGD individuals; and (3) evaluate the feasibility and acceptability of the adapted intervention in a pilot randomized controlled trial.
Interventions
- BEHAVIORAL Enhanced Treatment As Usual (ETAU)
- BEHAVIORAL PRIDE QUIT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2024-09-01 |
| Est. Completion | 2025-03-21 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06654414
The ClinicalTrials.gov registry entry for NCT06654414 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Enhanced Treatment As Usual (ETAU) is the first listed.
NCT06654414 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06654414 about?
NCT06654414 is a clinical study titled "Project QUIT+: Adapting and Testing a Smoking Cessation Intervention for Transgender and Gender Expansive Individuals". Smoking remains the leading preventable cause of death in the United States, and there are persistent and significant disparities in tobacco use among transgender and gender diverse (TGD) individuals. Stigma, discrimination, gender dysphoria, and other gender minority stressors likely contribute to ...
What is the current status of trial NCT06654414?
This trial is currently terminated. It is a NA study. The enrollment target is 3 participants. The study started on 2024-09-01. Estimated completion is 2025-03-21.
What interventions are being tested in trial NCT06654414?
The interventions under investigation include: Enhanced Treatment As Usual (ETAU) (BEHAVIORAL), PRIDE QUIT (BEHAVIORAL).
Who is sponsoring clinical trial NCT06654414?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.